Citations

Showing 10 of 108152 citations.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission
Rashidi, Armin , Hamadani, Mehdi , Zhang, Mei-Jie , Wang, Hai-Lin, Abdel‐Azim, Hisham , Aljurf, Mahmoud , Assal, Amer , Bashey, Asad, Beitinjaneh, Amer , Bejanyan, Nelli , Bolaños‐Meade, Javier , Byrne, Michael , Cahn, Jean‐Yves, Cairo, Mitchell S. , Ciurea, Stefan O. , Copelan, Edward A. , Daly, Andrew , Diaz, Miguel-Angel, Farhadfar, Nosha , Ganguly, Siddhartha , Hahn, Theresa , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Holland, H. Kent, Hossain, Nasheed , Kanakry, Christopher G. , Kharfan‐Dabaja, Mohamed A. , Khera, Nandita , Martino, Rodrigo , Munker, Reinhold , Murthy, Hemant S. , Nakamura, Ryotaro , Nathan, Sunita , Palmisiano, Neil , Patel, Sagar S. , Pidala, Joseph, Olin, Rebecca L. , Olsson, Richard F. , Ringdén, Olle , Rizzieri, David A. , Rowe, Jacob M. , Savoie, Mary Lynn , Seo, Sachiko , Shaffer, Brian C. , Singh, Anurag K. , Solh, Melhem , Stockerl‐Goldstein, Keith , Verdonck, Leo F. , Wagner, John L. , Waller, Edmund K. , Litzow, Mark R. , Weisdorf, Dan, Saber, Wael , Weisdorf, Daniel J. , Wagner, John E. , Gale, Robert P , Hashmi, Shahrukh K , Hildebrandt, Gerhard C , Kharfan-Dabaja, Mohamed A., McGuirk, Joseph , Murthy, Hemant S , Nishihori, Taiga , Patel, Sagar , Olsson, Richard F , Ringden, Olov , Savoie, Mary Lynn , Wagner, John , Waller, Edmund K , Sandmaier, Brenda M , Litzow, Mark R. , Weisdorf, Dan , Hamadani, Mehdi , Assal, Amer , Martino, Rodrigo , Zhang, Mei‐Jie , Bajel, Ashish R. , Battiwalla, Minoo , Bhatt, Vijaya Raj , Cahn, Jean‐Yves , Cutler, Corey S. , Gale, Robert Peter , Grunwald, Michael R. , Koç, Yener , Lazarus, Hillard M. , Lee, Jong Wook , Maertens, Johan A. , McGuirk, Joseph P. , Nishihori, Taiga , Oran, Betül , Schultz, Kirk R. , Lima, Marcos de , Romee, Rizwan , Rashidi, Armin , Stockerl-Goldstein, Keith

Mayo Clinic

Blood Advances | June 14, 2019 | Volume: 3 | Issue: 12 | Pages: 1826-1836

10.1182/bloodadvances.2019000050 | PMID 31201170 Get It

Abstract HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy–based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease–donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy–based Haplo-HCT vs MSD using calcineurin inhibitor–based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.
The Association of Late-Life Diabetes Status and Hyperglycemia With Incident Mild Cognitive Impairment and Dementia: The ARIC Study
Sharrett, A. Richey, Albert, Marilyn , Windham, B. Gwen , Burgard, Sheila , Selvin, Elizabeth , Selvin, Elizabeth , Selvin, Elizabeth , Rawlings, Andreea M. , Coresh, Josef , Power, Melinda C. , Knopman, David S. , Walker, Keenan A. , Mosley, Thomas H. , Gottesman, Rebecca F.

Mayo Clinic

Diabetes Care | June 14, 2019 | Volume: 42 | Issue: 7 | Pages: 1248-1254

10.2337/dc19-0120 | PMID 31221696 Get It

OBJECTIVE We sought to examine associations in older adults among diabetes, glycemic control, diabetes duration, and biomarkers of hyperglycemia with incident mild cognitive impairment (MCI) and incident dementia. RESEARCH DESIGN AND METHODS We conducted a prospective analysis of 5,099 participants from the Atherosclerosis Risk in Communities (ARIC) Study who attended the fifth (2011–2013) exam. Cognitive status was assessed during follow-up via telephone calls, death certificate codes, surveillance, and a follow-up examination (2016–2017). We defined incident cognitive impairment as incident MCI or incident dementia in persons dementia-free at the index examination; we also examined each outcome separately. Diabetes was defined using self-report, medications, or HbA1c ≥6.5%; poor glycemic control in persons with diabetes was defined as HbA1c ≥7%. We examined the following biomarkers of hyperglycemia: HbA1c, fructosamine, glycated albumin, and 1,5-anhydroglucitol. RESULTS Mean age at baseline was 76 years, 59% were female, and 21% were black. Diabetes (hazard ratio [HR] 1.14 [95% CI 1.00, 1.31]), poor glycemic control in persons with diabetes (HR 1.31 [95% CI 1.05, 1.63]), and longer diabetes duration (≥5 vs. <5 years; HR 1.59 [95% CI 1.23, 2.07]) were significantly associated with incident cognitive impairment. We found a J-shaped association between HbA1c and incident dementia. Glycated albumin and fructosamine were also associated with incident dementia, independently of HbA1c. HbA1c and fructosamine were also associated with incident MCI. CONCLUSIONS Diabetes status, poor glycemic control, and longer diabetes duration were associated with worse cognitive outcomes over a median follow-up of 5 years.
Biological analysis of flexor tendon repair-failure stump tissue: a potential recycling of tissue for tendon regeneration
Lu, Cheng‐Chang , Zhang, T., Reisdorf, Ramona L., Amadio, Peter C. , An, K-N, Moran, Steven L. , Gingery, Anne , Zhao, Chunfeng , An, K-N., Gingery, Anne

Mayo Clinic

Bone & Joint Research | June 14, 2019 | Volume: 8 | Issue: 6 | Pages: 232-245

10.1302/2046-3758.86.bjr-2018-0239.r1 | PMID 31346451 Get It

Objectives Re-rupture is common after primary flexor tendon repair. Characterization of the biological changes in the ruptured tendon stumps would be helpful, not only to understand the biological responses to the failed tendon repair, but also to investigate if the tendon stumps could be used as a recycling biomaterial for tendon regeneration in the secondary grafting surgery. Methods A canine flexor tendon repair and failure model was used. Following six weeks of repair failure, the tendon stumps were analyzed and characterized as isolated tendon-derived stem cells (TDSCs). Results Failed-repair stump tissue showed cellular accumulation of crumpled and disoriented collagen fibres. Compared with normal tendon, stump tissue had significantly higher gene expression of collagens I and III, matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF). The stump TDSCs presented both mesenchymal stem and haematopoietic cell markers with significantly increased expression of CD34, CD44, and CD90 markers. Stump TDSCs exhibited similar migration but a lower proliferation rate, as well as similar osteogenic differentiation but a lower chondrogenic/adipogenic differentiation capability, compared with normal TDSCs. Stump TDSCs also showed increasing levels of SRY-box 2 (Sox2), octamer-binding transcription factor 4 (Oct4), tenomodulin (TNMD), and scleraxis (Scx) protein and gene expression. Conclusion We found that a failed repair stump had increased cellularity that preserved both mesenchymal and haematopoietic stem cell characteristics, with higher collagen synthesis, MMP, and growth factor gene expression. This study provides evidence that tendon stump tissue has regenerative potential. Cite this article: C-C. Lu, T. Zhang, R. L. Reisdorf, P. C. Amadio, K-N. An, S. L. Moran, A. Gingery, C. Zhao. Biological analysis of flexor tendon repair-failure stump tissue: A potential recycling of tissue for tendon regeneration. Bone Joint Res 2019;8:232–245. DOI: 10.1302/2046-3758.86.BJR-2018-0239.R1.
Association between contact sports participation and chronic traumatic encephalopathy: a retrospective cohort study
Bieniek, Kevin F. , Blessing, Melissa M. , Diehl, Nancy N. , Serie, Amanda M., Paolini, Michael A., Savica, Rodolfo , Reichard, R. Ross , Heckman, Michael G. , Boeve, Bradley F. , Dickson, Dennis W.

Mayo Clinic

Brain Pathology | June 14, 2019 | Volume: 30 | Issue: 1 | Pages: 63-74

10.1111/bpa.12757 | PMID 31199537 Get It

AbstractChronic traumatic encephalopathy is a debilitating neurodegenerative disorder associated with repetitive traumatic brain injuries often sustained through prior contact sport participation. The frequency of this disorder in a diverse population, including amateur athletes, is unknown. Primary historical obituary and yearbook records were queried for 2566 autopsy cases in the Mayo Clinic Tissue Registry resulting in identification of 300 former athletes and 450 non‐athletes. In these cases, neocortical tissue was screened for tau pathology with immunohistochemistry, including pathology consistent with chronic traumatic encephalopathy, blinded to exposure or demographic information. Using research infrastructure of the Rochester Epidemiology Project, a comprehensive and established medical records‐linkage system of care providers in southern Minnesota and western Wisconsin, medical diagnostic billing codes pertaining to head trauma, dementia, movement disorders, substance abuse disorders and psychiatric disorders were recorded for cases and controls in a blinded manner. A total of 42 individuals had pathology consistent with, or features of, chronic traumatic encephalopathy. It was more frequent in athletes compared to non‐athletes (27 cases versus 15 cases) and was largely observed in men (except for one woman). For contact sports, American football had the highest frequency of chronic traumatic encephalopathy pathology (15% of cases) and an odds ratio of 2.62 (P‐value = 0.005). Cases with chronic traumatic encephalopathy pathology had higher frequencies of antemortem clinical features of dementia, psychosis, movement disorders and alcohol abuse compared to cases without chronic traumatic encephalopathy pathology. Understanding the frequency of chronic traumatic encephalopathy pathology in a large autopsy cohort with diverse exposure backgrounds provides a baseline for future prospective studies assessing the epidemiology and public health impact of chronic traumatic encephalopathy and sports‐related repetitive head trauma.
Electrophysiologic effects and outcomes of sympatholysis in patients with recurrent ventricular arrhythmia and structural heart disease
Cai, Cheng , Dai, Mingyan , Tian, Ying , Zhang, Pei , Wittwer, Erica D. , Rho, Richard H., Mulpuru, Siva K. , Lee, Hon‐Chi, Ackerman, Michael J. , Asirvatham, Samuel J. , Munger, Thomas M. , Friedman, Paul A. , Cha, Yong‐Mei , Dai, Ming-Yan, Kapa, Suraj , Mulpuru, Siva K , Asirvatham, Samuel J , Chen, Ming-Long , Friedman, Paul A , Cha, Yong-Mei , Kapa, Suraj , McLeod, Christopher J.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 14, 2019 | Volume: 30 | Issue: 9 | Pages: 1499-1507

10.1111/jce.14030 | PMID 31199536 Get It

AbstractIntroductionAutonomic modulation has been used as a therapy to control recurrent ventricular arrhythmia (VA). This study was to explore stellate ganglion block (SGB) effect on cardiac electrophysiologic properties and evaluate the long‐term outcome of cardiac sympathetic denervation (CSD) for patients with recurrent VA and structural heart disease (SHD).Materials and MethodsPatients who had recurrent VA due to SHD were enrolled prospectively. Electrophysiologic study and ventricular tachycardia (VT) induction were performed before and after left and right SGB. VA burden and long‐term outcomes were assessed for a separate patient group who underwent left or bilateral CSD for drug‐refractory VA due to SHD.ResultsElectrophysiologic study of nine patients showed that baseline mean (SD) corrected sinus node recovery time (cSNRT) increased from 320.4 (73.3) ms to 402.9 (114.2) ms after left and 482.4 (95.7) ms after bilateral SGB (P = .03). SGB did not significantly change P‐R, QRS, and Q‐T intervals and ventricular effective refractory period, nor did the inducibility of VA. Nineteen patients underwent left (n = 14) or bilateral (n = 5) CSD. CSD reduced VA burden and appropriate ICD therapies from a median (interquartile range) of 2.5 (0.4‐11.6) episodes weekly to 0.1 (0.0‐2.4) episodes weekly at 6‐month follow‐up (P = .002). Three‐year freedom from orthotopic heart transplant (OHT) and death was 52.6%. New York Heart Association functional class III/IV and VT rate less than 160 beats per minute were predictors of recurrent VA, OHT, and death.ConclusionSGB increased cSNRT without changing heart rate. CSD was more beneficial for patients with mild‐to‐moderate heart failure and faster VA.
Arabinose Alters Both Local and Distal H–D Exchange Rates in the Escherichia coli AraC Transcriptional Regulator
Tischer, Alexander , Brown, Matthew J. , Schleif, Robert , Auton, Matthew , Auton, Matthew , Tischer, Alexander , Brown, Matthew J.

Mayo Clinic

Biochemistry | June 14, 2019 | Volume: 58 | Issue: 26 | Pages: 2875-2882

10.1021/acs.biochem.9b00389 | PMID 31199144 Get It

National trends in prescription drug expenditures and projections for 2019
Schumock, Glen T., Stubbings, JoAnn , Hoffman, James M. , Wiest, Michelle D., Suda, Katie J. , Rim, Matthew H, Tadrous, Mina , Tichy, Eric M. , Cuéllar, Sandra , Clark, John Spencer , Matusiak, Linda M., Hunkler, Robert J., Vermeulen, Lee C.

Mayo Clinic

American Journal of Health-System Pharmacy | June 14, 2019 | Volume: 76 | Issue: 15 | Pages: 1105-1121

10.1093/ajhp/zxz109 | PMID 31199861 Get It

AbstractPurposeHistorical trends and factors likely to influence future pharmaceutical expenditures are discussed, and projections are made for drug spending in 2019 in nonfederal hospitals, clinics, and overall (all sectors).MethodsDrug expenditure data through calendar year 2018 were obtained from the IQVIA National Sales Perspectives database and analyzed. New drug approvals, patent expirations, and other factors that may influence drug spending in hospitals and clinics in 2019 were also reviewed. Expenditure projections for 2019 for nonfederal hospitals, clinics, and overall (all sectors) were made through a combination of quantitative analyses and expert opinion.ResultsU.S. prescription sales in calendar year 2018 totaled $476.2 billion, a 5.5% increase from 2017 spending. The top 3 drugs by expenditures were adalimumab ($19.1 billion), insulin glargine ($9.3 billion), and etanercept ($8.0 billion). Prescription expenditures in nonfederal hospitals totaled $35.8 billion, a 4.8% increase from 2017. Expenditures in clinics in 2018 increased by 13.0% to $80.5 billion. The increase in spending in nonfederal hospitals was largely driven by new products and increased utilization of existing products. The list of the top 25 drugs by expenditures in nonfederal hospitals and clinics was dominated by specialty drugs.ConclusionWe predict continued moderate growth of 4–6% in overall drug expenditures (across the entire U.S. market). We expect the clinic sector to continue to experience high (11–13%) growth in drug spending in 2019. Finally, for nonfederal hospitals we anticipate growth in the range of 3–5%. These estimates are at the national level. Health-system pharmacy leaders should carefully examine local drug utilization patterns to determine their own organization’s anticipated spending in 2019.
Third-Party Coverage for Aphakic Contact Lenses for Children
Kruger, Stacey J. , VanderVeen, Deborah K. , Bothun, Erick D. , Drews‐Botsch, Carolyn , Lambert, Scott R. , Group, for the Infant Aphakia Study, Bothun, Erick, Freedman, Sharon F. , Group, for the Infant Aphakia Study

Mayo Clinic

Translational Vision Science & Technology | June 14, 2019 | Volume: 8 | Issue: 3 | Pages: 41

10.1167/tvst.8.3.41 | PMID 31231593 Get It

Taking a closer look at whole organisms
Ichino, Noriko , Ekker, Stephen C. , Ekker, Stephen C , Ichino, Noriko

Mayo Clinic

eLife | June 14, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.7554/elife.48340 | PMID 31199245 Get It

By enabling researchers to image whole zebrafish with cellular resolution, X-ray histotomography will improve our understanding of the biological differences between individuals of the same species.
Letter by Kallmes et al Regarding Article, “Mechanical Thrombectomy in Ischemic Stroke Patients With Alberta Stroke Program Early Computed Tomography Score 0–5”
Kallmes, David F. , Brinjikji, Waleed , Rabinstein, Alejandro A.

Mayo Clinic

Stroke | June 14, 2019 | Volume: 50 | Issue: 7 | Pages: No page available

10.1161/strokeaha.119.025741 | PMID 31195939 Get It